logo

Seelos Therapeutics, Inc (SEEL)



Trade SEEL now with
  Date
  Headline
9/23/2020 9:04:32 AM Seelos Announces Sponsored Research Deal With Duke University For Gene Therapy Studies Of SLS-004 In Parkinson's Disease
9/14/2020 9:05:43 AM Seelos Announces Issuance Of New Patent And Additional Notice Of Allowance In Japan For Intranasal Racemic Ketamine
9/10/2020 9:07:32 AM Seelos Therapeutics Receives Notice Of Allowance For An Additional US Patent For Trehalose
9/9/2020 2:30:09 PM Seelos Therapeutics Announces Closing Of $7 Mln Registered Direct Offering
9/4/2020 9:13:08 AM Seelos Therapeutics Reports Pricing Of $7.0 Mln Direct Offering
8/25/2020 11:10:39 AM Seelos Therapeutics Granted Orphan Drug Designation For SLS-005 In MPS III Sanfilippo Syndrome From EMA
8/10/2020 9:21:01 AM Seelos Receives FDA May Proceed Notice To Initiate Phase IIb/III Trial Of SLS-005 In Amyotrophic Lateral Sclerosis
7/21/2020 9:08:52 AM Seelos Therapeutics Gets Positive EMA Opinion On Orphan Drug Designation For SLS-005 In Sanfilippo Syndrome
6/23/2020 7:18:41 AM Seelos Therapeutics Announces Final Safety Data From Phase I PK/PD Study Of SLS-002
5/28/2020 7:06:47 AM Seelos Therapeutics Begins Preclinical Study Of SLS-004 In Parkinson's Disease
5/4/2020 8:12:09 AM Seelos Therapeutics Receives Notice Of Allowance For Additional US Patent For Trehalose
4/8/2020 9:34:11 AM Seelos Expects To Release Addl Safety Data On Phase I Studies Of SLS-002 In Q2
3/11/2020 9:03:06 PM Seelos Therapeutics Announces Pricing Of Underwritten Public Offering Of 7.50 Mln Shares At $0.60/shr
3/11/2020 8:14:21 AM Seelos Therapeutics Announces EMA Guidance To Design An Open-Label Pivotal Study For SLS-005 In Sanfilippo Syndrome
3/6/2020 8:08:29 AM Seelos Therapeutics Receives Notice Of Allowance From USPTO For Composition Of Matter Patent For SLS-007